Have questions?
Contact UsCondition
Amyotrophic Lateral Sclerosis (ALS)Compensation
VariableDuration
Amyotrophic Lateral Sclerosis (ALS)
Official Title
Amyotrophic Lateral Sclerosis (ALS)
Study Summary
This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in participants with amyotrophic lateral sclerosis (ALS) to explore safety, tolerability, and pharmacokinetic (PK) properties of GDC-0134. It will include three components: a Single-Ascending-Dose (SAD) stage, a Multiple-Ascending-Dose (MAD) stage, and an Open-Label Safety Expansion (OSE) stage.
Eligibility and Recruitment Information
Recruitment Status | Recruiting |
---|---|
Eligible Genders | Both |
Eligible Ages | 18+ |
Inclusion | ALS Diagnosis |
Exclusion | ALS Diagnosis |
Start Date | |
Compensation | Variable |
Location | Orlando, FL |
Study Information
Condition | Amyotrophic Lateral Sclerosis (ALS) |
---|---|
Study Phase | Phase 1 |
Administrative Information
Study ID | NEUROLOGICAL |
---|---|
Investigators |
Ira Goodman, MD |